CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 6 enrolled
Drug / intervention
Atezolizumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03483012
NCT03483012Phase 2Completed
CompareCT.gov

A Phase II Study of Atezolizumab in Combination With Stereotactic Radiation for Patients With Triple-negative Breast Cancer and Brain Metastasis

Dana-Farber Cancer Institute·interventional·Posted Mar 29, 2018·Updated Apr 21, 2026

In Brief

A Phase 2 clinical trial evaluating Atezolizumab and Stereotactic radiosurgery (SRS) for Breast Cancer. Completed, enrolled 6 participants across 1 site.

Detailed Summary

This research study is studying the combination of a drug called atezolizumab and a radiation procedure called stereotactic radiosurgery (SRS) as a possible treatment for triple-negative breast cancer that has spread to the brain. The interventions involved in this study are: * Atezolizumab * Stereotactic radiosurgery (SRS)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States
CollaboratorsGenentech, Inc.

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedMar 29, 2018
Enrollment StartMay 1, 2018
Primary CompletionNov 21, 2019
Study CompletionNov 12, 2025
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 8.3 years ago

Interventions

Atezolizumabdrug

Atezolizumab is a protein that affects your immune system by blocking the PD-L1 pathway

Stereotactic radiosurgery (SRS)procedure

Stereotactic radiosurgery (SRS) is a standard procedure used to treat patients with cancer in the brain. SRS uses many precisely focused radiation beams to treat tumors